Sarepta Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (contained on signature page)
POWER OFATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Douglas S. Ingram and Ian M. Estepan, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file, any and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their and his or her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on February 28, 2024:
| Signature | Title |
|---|---|
| /s/ Douglas S. Ingram | President, Chief Executive Officer and Director (Principal Executive Officer) |
| Douglas S. Ingram | |
| /s/ Ian M. Estepan | Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) |
| Ian M. Estepan | |
| /s/ M. Kathleen Behrens | Chairwoman of the Board |
| M. Kathleen Behrens, Ph.D. | |
| /s/ Richard Barry | Director |
| Richard Barry | |
| /s/ Kathryn Boor | Director |
| Kathryn J. Boor, Ph.D. | |
| /s/ Michael A. Chambers | Director |
| Michael A. Chambers | |
| /s/ Stephen L. Mayo | Director |
| Stephen L. Mayo, Ph.D. | |
| /s/ Claude Nicaise | Director |
| Claude Nicaise, MD | |
| /s/ Hans Wigzell | Director |
| Hans Wigzell, M.D., Ph.D. | |
-95-
SAREPTA THERAPEUTICS, INC.
CONSOLIDATED FINANCIAL STATEMENTS
| PageNumber | |
| Report of Independent Registered Public Accounting Firm (KPMG LLP, Boston, MA, Auditor Firm ID: 185) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.